Quantum Biopharma (NASDAQ:QNTM) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Quantum Biopharma (NASDAQ:QNTM) from a hold rating to a sell rating in a research report report published on Saturday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Quantum Biopharma in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Quantum Biopharma Price Performance

Shares of Quantum Biopharma stock opened at $4.88 on Friday. The business has a 50-day moving average of $3.67 and a 200-day moving average of $6.35. The company has a market capitalization of $18.63 million, a PE ratio of -0.59 and a beta of 0.29. Quantum Biopharma has a 1-year low of $2.07 and a 1-year high of $38.25.

Quantum Biopharma (NASDAQ:QNTM) last announced its earnings results on Thursday, March 26th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.49).

Hedge Funds Weigh In On Quantum Biopharma

A number of hedge funds have recently bought and sold shares of QNTM. Jane Street Group LLC acquired a new position in Quantum Biopharma in the fourth quarter worth about $80,000. Virtu Financial LLC acquired a new position in Quantum Biopharma in the fourth quarter worth about $76,000. Finally, Platform Technology Partners acquired a new position in Quantum Biopharma in the first quarter worth about $199,000. 1.24% of the stock is currently owned by institutional investors and hedge funds.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.